Abraham, Mabel N.
Nedeljkovic-Kurepa, Ana
Fernandes, Tiago D.
Yaipen, Omar
Brewer, Mariana R.
Leisman, Daniel E.
Taylor, Matthew D.
Deutschman, Clifford S. http://orcid.org/0000-0001-9490-4024
Funding for this research was provided by:
National Institute of General Medical Sciences (R01GM121102, K08GM132794)
Article History
Received: 13 September 2023
Accepted: 21 January 2024
First Online: 5 February 2024
Declarations
:
: All animal studies were approved by the Feinstein Institute IACUC (2017-013 Term I & II) and conformed to ARRIVE guidelines.
: All authors have reviewed the manuscript and agreed to participate.
: The authors declare the following competing interests: All the work was performed at the Feinstein Institutes for Medical Research (FIMR) and all authors worked at FIMR at one time or another. CSD and MDT hold faculty appointments in the Institute for Molecular Medicine at the FIMR. CSD receives an annual stipend from the Society of Critical Care Medicine to serve as Scientific Editor for the journal <i>Critical Care Medicine</i>. He is an unpaid member of the editorial board of the journal <i>Shock</i>. CSD has received consultant’s fees from the Siemens Healthcare Diagnostics Inc. (Tarrytown NY, USA). He received stock options in Enlivex Co. (Jerusalem, Israel) as a consult and ICON Clinical Research LLC for participation on a Data Safety Management Board. He has received royalties from Elsevier Inc. as Editor of the textbook <i>Evidence-based Practice of Critical Care</i>. MDT and CSD have received Giapreza (angiotensin II) for experimental use from La Jolla Pharmaceuticals (La Jolla CA).